Last Updated: May 10, 2026

Profile for Australia Patent: 2006283517

✉ Email this page to a colleague

US Patent Family Members and Approved Drugs for Australia Patent: 2006283517

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

Glossary

Subscribe to access the full database, or Start Trial
US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
⤷ Start Trial	Feb 18, 2027	Astrazeneca Ab	BYDUREON	exenatide synthetic
⤷ Start Trial	Feb 18, 2027	Astrazeneca Ab	BYDUREON PEN	exenatide synthetic
⤷ Start Trial	Feb 18, 2027	Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic
>US Patent Number	>US Expiration Date	>US Applicant	>US Tradename	>Generic Name

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.